TickerTalks
Browse all tickers →
TickerTalks›$GRAL
GRGRAL

GRAIL Inc.

$GRAL·$5.4B·Medical - Diagnostics & Research·Healthcare
$136.57+3.0%YTD+57.0%1Y+125.7%
Price updated 5h ago·X counts updated 2d ago
GRGRAL
$GRALGRAIL Inc.
$136.57+2.97%517 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $GRAL on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

517X posts · last 7 days
Sep 20Sep 27
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $GRAL's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-09-29

GRAIL holders are euphoric after the FDA advisory committee voted in favor of Galleri approval, sending the stock +57% in eight sessions and +97% since original bullish coverage. Targets stack up at $148/$166/$196, and the Galleri MCED test targets 50+ cancer types with no routine screening today; no bear voice in the window.

Read what X is saying about $GRAL

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $GRAL — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-09-28

The move is getting stronger, with heavier trading behind it.

GRAIL's multi-cancer blood test got a positive FDA committee vote — real regulatory catalyst, and the CEO cashed out $6M into the news.

GRAIL is developing the Galleri multi-cancer early-detection blood test — an ambitious screening tool that would detect dozens of cancer types from a single blood draw. An FDA advisory committee just voted for premarket approval, and the stock is up 163% in the past year on the resulting revaluation.

  • The commercial trajectory is now conditional on final FDA approval: analysts see revenue moving from ~$181M this year to $477M by 2030 as reimbursement expands, but the model requires full FDA approval to unlock large-scale insurer coverage.
  • The financial cost of the story is enormous: consensus 2026 EPS is -$9.62, operating margin at -338%, and free cash flow negative — this is a pre-approval biotech, not a compounder yet.
  • The insider tape just went heavy: CEO Ofman exercised $14 options and immediately sold 61,452 shares for $6M at $97.74, plus CFO Freidin sold $383K — the largest insider-distribution cluster since the FDA committee vote, and a real cash-out signal into the good news.

Watch for the final FDA decision timeline and the November 11 earnings for any CMS reimbursement color — a full FDA approval with CMS coverage clarity restarts the tape decisively; a delayed approval or a limited-population label is what turns the current acceleration into a real drawdown from these highs.

What to watch: Final FDA approval decision and November 11 earnings for CMS reimbursement color — a full FDA approval with CMS coverage clarity restarts the tape, a delayed approval or limited-population label turns acceleration into a real drawdown.

On the calendar: 2026-11-11 — Q3 earnings

sentiment missing

Read the AI verdict on $GRAL

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Commercializes Galleri, a multi-cancer early detection blood test using cell-free DNA methylation sequencing.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $GRAL.

Medical - Diagnostics & Research · Healthcare

Genetic testing, liquid biopsy, and multi-cancer early detection (MCED) platforms are growing through direct-to-consumer and employer wellness channels; reimbursement coverage expansion by CMS and commercial payers is the adoption bottleneck. Lab volume normalization post-COVID is complete; growth is now driven by novel test launches and test menu expansion for chronic disease management.

What this means for $GRAL

Partial — Commercializes Galleri, a multi-cancer early detection blood test using cell-free DNA methylation sequencing.

Industry benchmark

18-name peer basket
+44.5%YTD
+75.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-11.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-14.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-338%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
28.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-15.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-10.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-2.56$-2.66+3.8%
Q1 2026May 5, 2026$-2.29$-2.76+17.1%
Q4 2025Feb 19, 2026$-2.44$-3.33+26.7%
Q3 2025Nov 12, 2025$-2.46$-3.36+26.8%
Next earningsWed, Nov 11·consensus EPS $-2.51

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$44.7M+25.7%-28.1%-389%$-2.56$-81.2M
Q1 FY26$40.8M+28.1%47.9%-333%$-2.29$-87.5M
Q4 FY25$43.6M+14.0%-25.5%-285%$-2.44$-63.0M
Q3 FY25$36.2M+26.3%-37.9%-346%$-2.46$-63.6M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$180.9M$177.9M – $183.8M-$9.62-$10.28 – -$9.048
FY27$226.8M$214.3M – $245.7M-$10.19-$10.55 – -$9.788
FY28$287.3M$245.0M – $354.4M-$9.69-$12.01 – -$8.2310
FY29$371.2M$346.9M – $406.3M-$10.33-$11.59 – -$9.455
FY30$477.7M$446.4M – $522.8M-$9.54-$10.72 – -$8.735

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.96%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+69.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+87.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 39.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β3.255-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 21Aaron FreidinCFO4.1K sh$383KSellSep 21Joshua J. OfmanCEO61.5K sh$6.0MSellAug 27Joshua J. OfmanCEO5.0K sh$425KSellAug 27Aaron FreidinCFO7.9K sh$672KSellJun 4Partridge Andrew JohnChief Growth Officer1.5K sh$91KSellApr 8Aaron FreidinCFO45.8K sh$2.3MSellApr 8Robert P RagusaCEO123.5K sh$6.2MSellApr 8Joshua J. OfmanPresident61.7K sh$3.1M
+ 13 other (12 awards · 1 exempt) in window

See when $GRAL insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 228-K — Item 5.07: Shareholder vote
3New insider — initial holdingsJun 23
8-KOfficer or director changeJun 18-K — Item 5.02: Officer or director change · Item 8.01: Other event
+ 12 other (6 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $382,694.00 in Stockdefenseworld.net·4d agoHere's Why Grail Stock Surged 55% This Weekfool.com·5d agoGRAIL (NASDAQ:GRAL) CEO Joshua Ofman Sells 61,452 Sharesdefenseworld.net·6d agoOwning a Home Is Seen as a Financial Holy Grail. But What If It Isn't?wsj.com·6d agoGrail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approvalwsj.com·6d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$A$NTRA$ILMN$TMO$DHR$GH$BLLN
Voices on X · top 6 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport